Prognostic markers of survival after combined mitotane- and platinum-based chemotherapy in metastatic adrenocortical carcinoma
Open accessThe DOI matches its Crossref record; 10 of the 10 references it cites were found in a registry or an index.
Abstract
To progress in the stratification of the first-line therapeutic management of metastatic adrenocortical carcinoma (ACC), we searched for prognostic parameters of survival in patients treated with combined mitotane- and cisplatinum-based chemotherapy as first-line. We retrospectively studied prospectively collected parameters from 131 consecutive patients with metastatic ACC (44 with a tissue specimen available) treated at the Gustave Roussy Institute with mitotane- and platinum-based chemotherapy. Fifty-five patients with clinical, pathological, and morphological data available together with treatment characteristics including detailed follow-up were enrolled. Plasma mitotane levels and ERCC1 protein staining were analyzed. Response was analyzed according to RECIST criteria as well as overall survival (OS) from the start of cisplatinum-based chemotherapy. Parameters impacting on OS were evaluated by univariate analysis, and then analyzed by multivariate analysis. Using a landmark method, OS according to response to chemotherapy was analyzed. Objective response to combined mitotane- and cisplatinum-based chemotherapy was 27.3%. Median OS was 1 year. In the univariate analysis, resection of the primary, time since diagnosis, mitotane monotherapy as single first-line treatment, number of affected organs, plasma mitotane above 14 mg/l, and objective response were predictors of survival. In the multivariate analysis, mitotane level ≥14 mg/l and objective response to platinum-based chemotherapy were found to be independent predictors of survival (P=0.03 and <0.001). Our study suggests a prognostic role for mitotane therapy and objective response to platinum-based chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Optimal two-stage designs for phase II clinical trials.
Simon, R. (1989) · Controlled Clinical Trials · doi:10.1016/0197-2456(89)90015-9 · Cited by 3,636
Cisplatin: mode of cytotoxic action and molecular basis of resistance
Siddik, Z. H. (2003) · Oncogene · doi:10.1038/sj.onc.1206933 · Cited by 3,335
Adrenocortical Carcinoma: Clinical Update
Allolio, B., & Fassnacht, M. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2639 · Cited by 775
Fassnacht, M., Johanssen, S., Quinkler, M., Bucsky, P., Willenberg, H. S., Beuschlein, F., Terzolo, M., Mueller, H., Hahner, S., Allolio, B., et al. (2009) · Cancer · doi:10.1002/cncr.24030 · Cited by 695
Icard, P., Goudet, P., Charpenay, C., Andreassian, B., Carnaille, B., Chapuis, Y., Cougard, P., Henry, J., & Proye, C. (2001) · World Journal of Surgery · doi:10.1007/s00268-001-0047-y · Cited by 543
Adrenocortical carcinoma in the United States: Treatment utilization and prognostic factors
Bilimoria, K. Y., Shen, W. T., Elaraj, D., Bentrem, D. J., Winchester, D. J., Kebebew, E., & Sturgeon, C. (2008) · Cancer · doi:10.1002/cncr.23886 · Cited by 493
Abiven, G., Coste, J., Groussin, L., Anract, P., Tissier, F., Legmann, P., Dousset, B., Bertagna, X., & Bertherat, J. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2005-2730 · Cited by 435
Prognostic parameters of metastatic adrenocortical carcinoma
Assié, G., Antoni, G., Tissier, F., Caillou, B., Abiven, G., Gicquel, C., Leboulleux, S., Travagli, J.-P., Dromain, C., Bertagna, X., et al. (2007) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0706 · Cited by 236 · cited 1×
“In addition, one study previously analyzed prognostic parameters of stage IV ACC patients at the time of metastatic disease discovery (Assie et al. 2007).”
BackgroundSelf-citationPreclinical targeting of the type I insulin-like growth factor receptor in adrenocortical carcinoma
Barlaskar, F. M., Spalding, A. C., Heaton, J. H., Kuick, R., Kim, A. C., Thomas, D. G., Giordano, T. J., Ben-Josef, E., & Hammer, G. D. (2009) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-1456 · Cited by 189
Response to mitotane predicts outcome in patients with recurrent adrenal cortical carcinoma
Gonzalez, R. J., Tamm, E. P., Ng, C., Phan, A. T., Vassilopoulou-Sellin, R., Perrier, N. D., Evans, D. B., & Lee, J. E. (2007) · Surgery · doi:10.1016/j.surg.2007.09.006 · Cited by 84
Cited by
Fassnacht, M., Dekkers, O. M., Else, T., Baudin, E., Berruti, A., de Krijger, R. R., Haak, H. R., Mihai, R., Assie, G., & Terzolo, M. (2018) · European Journal of Endocrinology · doi:10.1530/eje-18-0608 · Cited by 961
Self-citationCombination Chemotherapy in Advanced Adrenocortical Carcinoma
Fassnacht, M., Terzolo, M., Allolio, B., Baudin, E., Haak, H., Berruti, A., Welin, S., Schade-Brittinger, C., Lacroix, A., Jarzab, B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200966 · Cited by 873
Self-citationAdrenocortical carcinoma: a clinician’s update
Fassnacht, M., Libé, R., Kroiss, M., & Allolio, B. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.235 · Cited by 396
Kerkhofs, T. M. A., Verhoeven, R. H. A., Van der Zwan, J. M., Dieleman, J., Kerstens, M. N., Links, T. P., Van de Poll-Franse, L. V., & Haak, H. R. (2013) · European Journal of Cancer · doi:10.1016/j.ejca.2013.02.034 · Cited by 341
Fassnacht, M., Berruti, A., Baudin, E., Demeure, M. J., Gilbert, J., Haak, H., Kroiss, M., Quinn, D. I., Hesseltine, E., Ronchi, C. L., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70081-1 · Cited by 339
Self-citation
Metadata
- Authors
- Malandrino, P., Al Ghuzlan, A., Castaing, M., Young, J., Caillou, B., Travagli, J.-P., Elias, D., de Baere, T., Dromain, C., Paci, A., Chanson, P., Schlumberger, M., Leboulleux, S., & Baudin, E.
- Venue
- Endocrine-Related Cancer
- Publisher
- Bioscientifica
- Published
- 2010-09
- Volume
- 17
- Issue
- 3
- Pages
- 797-807
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2108273340
- Cited by
- 62
- References
- 10
- FWCI
- 5.28
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.